Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OMED NASDAQ:PYRGF NASDAQ:VIRI NASDAQ:WHWK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOMEDOncoMed Pharmaceuticals$0.89$0.55▼$3.35$34.43M1.86768,904 shs1,201 shsPYRGFPyroGenesis Canada$0.28-1.0%$0.34$0.26▼$0.71$53.03M0.8412,289 shs12,358 shsVIRIVirios Therapeutics$4.84-0.7%$4.93$0.13▼$1.04$93.11M1.581.05 million shs7,725 shsWHWKWhitehawk Therapeutics$1.74-0.6%$0.00$1.21▼$3.81$82.44M0.55117,014 shs19,249 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOMEDOncoMed Pharmaceuticals0.00%0.00%0.00%0.00%0.00%PYRGFPyroGenesis Canada-1.05%-4.36%-14.98%-12.62%-53.85%VIRIVirios Therapeutics-0.72%+2.22%-2.32%-3.69%+2,191.47%WHWKWhitehawk Therapeutics-0.57%-10.77%-7.45%+173,999,900.00%+173,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOMEDOncoMed PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APYRGFPyroGenesis Canada0.3773 of 5 stars0.04.00.00.00.01.70.0VIRIVirios TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AWHWKWhitehawk TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOMEDOncoMed Pharmaceuticals 0.00N/AN/AN/APYRGFPyroGenesis Canada 0.00N/AN/AN/AVIRIVirios Therapeutics 2.00Hold$5.003.41% UpsideWHWKWhitehawk Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOMEDOncoMed Pharmaceuticals$44.42M0.00N/AN/A$1.25 per share0.00PYRGFPyroGenesis Canada$9.14M5.80N/AN/A($0.01) per share-28.31VIRIVirios TherapeuticsN/AN/AN/AN/A$0.20 per shareN/AWHWKWhitehawk Therapeutics$27.78M2.95N/AN/A$2.12 per share0.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOMEDOncoMed Pharmaceuticals-$8.10M-$0.16N/AN/AN/A-18.24%-13.14%-7.73%N/APYRGFPyroGenesis Canada-$21.12M-$0.01N/A∞N/A-115.14%N/A-60.81%N/AVIRIVirios Therapeutics-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%8/6/2025 (Estimated)WHWKWhitehawk Therapeutics-$63.69M$0.1610.88∞N/A99.42%-56.73%-48.68%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOMEDOncoMed PharmaceuticalsN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/AVIRIVirios TherapeuticsN/AN/AN/AN/AN/AWHWKWhitehawk TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOMEDOncoMed PharmaceuticalsN/A5.045.04PYRGFPyroGenesis CanadaN/A0.600.50VIRIVirios TherapeuticsN/A7.277.27WHWKWhitehawk TherapeuticsN/A18.9518.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOMEDOncoMed Pharmaceuticals45.16%PYRGFPyroGenesis Canada0.03%VIRIVirios Therapeutics9.05%WHWKWhitehawk Therapeutics52.08%Insider OwnershipCompanyInsider OwnershipOMEDOncoMed Pharmaceuticals20.32%PYRGFPyroGenesis Canada47.68%VIRIVirios Therapeutics12.20%WHWKWhitehawk Therapeutics49.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOMEDOncoMed Pharmaceuticals2238.69 millionN/AOptionablePYRGFPyroGenesis Canada90187.31 million96.34 millionNo DataVIRIVirios Therapeutics519.26 million16.91 millionOptionableWHWKWhitehawk Therapeutics4047.11 million23.60 millionN/AOMED, VIRI, WHWK, and PYRGF HeadlinesRecent News About These CompaniesWhitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 22, 2025 | prnewswire.comMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerAmerica Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?PepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?By Thomas Hughes | July 19, 2025View PepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?OMED, VIRI, WHWK, and PYRGF Company DescriptionsOncoMed Pharmaceuticals NASDAQ:OMEDOncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. It is developing Navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors; and Phase Ib clinical trials for patients with second-line metastatic colorectal cancer, as well as in Phase Ib clinical trial in patients with platinum-resistant ovarian cancer. The company is also developing Etigilimab (Anti-TIGIT, OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia/b clinical trials for patients with advanced or metastatic solid tumors. It has strategic alliances with Celgene Corporation for discovery, development, and commercialization of novel small molecule therapeutics; and Bayer Pharma AG for discovery, development, and commercialization of anti- cancer stem cell biologic and small molecule therapeutics targeting the Wnt signaling pathway. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California.PyroGenesis Canada NASDAQ:PYRGF$0.28 0.00 (-1.05%) As of 08/1/2025 03:58 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.Virios Therapeutics NASDAQ:VIRI$4.84 -0.04 (-0.72%) As of 07/31/2025Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.Whitehawk Therapeutics NASDAQ:WHWK$1.74 -0.01 (-0.57%) As of 08/1/2025 04:00 PM EasternAadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
